Literature DB >> 16822399

Hypercoagulable states and strokes.

Nena Matijevic, Kenneth K Wu.   

Abstract

Several hematologic disorders and hemostatic defects increase risk of ischemic stroke. A common feature of these disorders is the creation of a prothrombotic state, now commonly referred to as "hypercoagulable state." Hematologic diseases such as essential thrombocythemia, polycythemia vera, and thrombotic thrombocytopenic purpura clearly cause stroke. Effective treatment is now available for these disorders. Association of hemostatic defects with stroke risk is still at the investigational stage. Although a number of factors such as soluble thrombomodulin, fibrinogen, factor VIII, von Willebrand factor, and plasminogen activator inhibitor-1 are associated with stroke risk, their predictive values remain unknown. Furthermore, causal relationship has not been established.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822399     DOI: 10.1007/s11883-006-0011-2

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  50 in total

1.  Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update.

Authors:  G Maresca; A Di Blasio; R Marchioli; G Di Minno
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-06       Impact factor: 8.311

2.  Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease.

Authors:  Kenneth K Wu; Nena Aleksic; Christie M Ballantyne; Chul Ahn; Harinder Juneja; Eric Boerwinkle
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

3.  Protein Z in young survivors of ischemic stroke.

Authors:  Stanislaw Lopaciuk; Ksenia Bykowska; Hubert Kwiecinski; Anna Czlonkowska; Arletta Kuczynska-Zardzewialy
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

4.  Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study.

Authors:  Hugh S Markus; Beverley Hunt; Kiran Palmer; Christian Enzinger; Helena Schmidt; Reinhold Schmidt
Journal:  Stroke       Date:  2005-05-19       Impact factor: 7.914

5.  No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study.

Authors:  Adam M Smiles; Nancy S Jenny; Zhonghua Tang; Alice Arnold; Mary Cushman; Russell P Tracy
Journal:  Thromb Haemost       Date:  2002-04       Impact factor: 5.249

6.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

7.  Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts.

Authors:  Per-Gunnar Wiklund; Lennart Nilsson; Sofie Nilsson Ardnor; Per Eriksson; Lars Johansson; Birgitta Stegmayr; Anders Hamsten; Dan Holmberg; Kjell Asplund
Journal:  Stroke       Date:  2005-07-14       Impact factor: 7.914

8.  Frequency of protein Z deficiency in patients with ischaemic stroke.

Authors:  M Vasse; E Guegan-Massardier; J Y Borg; F Woimant; C Soria
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

9.  Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.

Authors:  A Santamaría; A Oliver; M Borrell; J Mateo; R Belvis; J Martí-Fábregas; R Ortín; I Tirado; J C Souto; J Fontcuberta
Journal:  Stroke       Date:  2003-08-28       Impact factor: 7.914

10.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more
  4 in total

1.  Effects of Danhong Injection (丹红注射液) and its main components on anticoagulation and fibrinolysis in cultured vein endothelial cells.

Authors:  Yu-yan Zhang; Hui-fen Zhou; Jie-hong Yang; Yu He; Xiao-qiang Chen; Katsuyoshi Nishinari; Hao-fang Wan; Hai-tong Wan
Journal:  Chin J Integr Med       Date:  2016-04-09       Impact factor: 1.978

2.  Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events.

Authors:  Matthew Gissel; Anetta Undas; Agnieszka Slowik; Kenneth G Mann; Kathleen E Brummel-Ziedins
Journal:  Thromb Res       Date:  2010-08-14       Impact factor: 3.944

3.  Association of Thrombin Generation With Leukocyte Inflammatory Profile in Patients With Acute Ischemic Stroke.

Authors:  Sarina Falcione; Danielle Munsterman; Twinkle Joy; Joseph Kamtchum-Tatuene; Gina Sykes; Glen Jickling
Journal:  Neurology       Date:  2022-07-05       Impact factor: 11.800

4.  Multiple recurrent ischaemic strokes in a patient with cancer: is there a role for the initiation of anticoagulation therapy for secondary stroke prevention?

Authors:  Giselle Alexandra Suero-Abreu; Jia Zhen Cheng; Ryna Karina Then
Journal:  BMJ Case Rep       Date:  2017-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.